Answers are grounded in this paper and cite their sources.
Previous studies suggested that treatment with low-dose arsenic trioxide (ATO) might reduce the risk of flares in patients with active systemic lupus erythematosus (SLE), but the underlying pharmacological mechanisms have not been investigated.
No takes yet. Share an insight, caveat, or question.
Yap et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: